Financial Performance - Revenue increased by approximately 1.6% to about RMB 74.7 million for the year ending December 31, 2024, compared to RMB 73.5 million for the year ending December 31, 2023[4] - Loss before tax was approximately RMB 30.1 million, worsening from a loss of approximately RMB 7.2 million for the year ending December 31, 2023[4] - Loss attributable to equity holders of the company was approximately RMB 32.4 million, compared to a loss of approximately RMB 13.6 million for the year ending December 31, 2023[4] - Basic and diluted loss per share attributable to ordinary equity holders of the parent was approximately RMB 5.57 cents, compared to RMB 2.27 cents for the year ending December 31, 2023[4] - Total comprehensive loss for the year was RMB 31.146 million, compared to RMB 12.206 million for the previous year[6] - The group reported a pre-tax loss of RMB 49,280,000 for 2024, compared to RMB 32,074,000 in 2023, indicating an increase in losses[24] - The net loss for the fiscal year ending December 31, 2024, was approximately RMB 32.6 million, compared to a net loss of RMB 13.6 million for the fiscal year ending December 31, 2023, indicating a significant increase in losses[39] Revenue Breakdown - Revenue from customer contracts for 2024 was RMB 74,680,000, an increase of 1.6% from RMB 73,513,000 in 2023[21] - Revenue for the reporting period was approximately RMB 74.7 million, an increase of about 1.6% compared to the fiscal year ending December 31, 2023, primarily due to contributions from two new facilities[54] - Revenue from the Oral Comprehensive Treatment Department was approximately RMB 30.5 million, a decrease of about 2.2% compared to the previous fiscal year, accounting for approximately 40.8% of total revenue[55] - Revenue from the Orthodontics Department was approximately RMB 14.1 million, a decrease of about 2.1% compared to the previous fiscal year, representing about 18.9% of total revenue[56] - Revenue from the Oral Rehabilitation Department was approximately RMB 16.3 million, an increase of RMB 1.4 million, accounting for about 21.8% of total revenue[57] - Revenue from the Implant Dentistry Department was approximately RMB 8.9 million, an increase of about 11.3% compared to the previous fiscal year, indicating a recovery in revenue[58] Expenses and Costs - Gross profit decreased to RMB 26.976 million from RMB 32.655 million, reflecting a decline in profitability[6] - Administrative expenses increased significantly to RMB 36.733 million from RMB 22.940 million, indicating rising operational costs[6] - Sales costs increased by approximately 16.6% to about RMB 47.7 million, attributed to rising employee costs and stock issuance rewards[59] - Selling expenses increased by approximately 10.1% to about RMB 22.8 million, mainly due to increased marketing and promotional expenses[62] - Employee benefits expenses increased to approximately RMB 52.2 million during the reporting period, compared to approximately RMB 33.4 million in the fiscal year 2023, an increase of RMB 18.8 million[72] Assets and Liabilities - Non-current assets increased to RMB 91,889 thousand in 2024 from RMB 80,117 thousand in 2023, representing a growth of 14.5%[8] - Current assets decreased to RMB 98,265 thousand in 2024 from RMB 152,310 thousand in 2023, a decline of 35.5%[8] - Total liabilities increased to RMB 69,756 thousand in 2024 from RMB 66,882 thousand in 2023, reflecting a rise of 4.2%[9] - The company's net asset value decreased to RMB 120,398 thousand in 2024 from RMB 165,545 thousand in 2023, a drop of 27.2%[9] - Cash and cash equivalents decreased to RMB 78,494 thousand in 2024 from RMB 86,827 thousand in 2023, a reduction of 9.5%[8] - The company reported a total equity of RMB 120,398 thousand in 2024, down from RMB 165,545 thousand in 2023, indicating a decrease of 27.2%[9] Taxation - The group's income tax expense for the fiscal year 2024 was RMB 2,478 thousand, a decrease from RMB 6,448 thousand in 2023[29] - The group has no income tax liabilities in Hong Kong for the fiscal year 2024 due to no taxable profits generated[8] - The group has a deferred tax expense of RMB 459 thousand for the fiscal year 2024, down from RMB 4,511 thousand in 2023[29] Corporate Governance and Shareholder Information - The board has resolved not to recommend the payment of a final dividend for the year ending December 31, 2024, compared to a dividend of HKD 0.01 per share for the year ending December 31, 2023[4] - The annual general meeting is scheduled for June 18, 2025, with a suspension of share transfer registration from June 13 to June 18, 2025[82][83] - The company has complied with all corporate governance codes applicable as of December 31, 2024, except for one specific provision[84] - The audit committee consists of three independent non-executive directors, who have reviewed the annual consolidated financial statements for the year ending December 31, 2024[89] Strategic Initiatives - The group is adjusting its business to respond to the national dental procurement policy, which has expanded to orthodontics, pediatric dentistry, and cosmetic dentistry[49] - The group aims to optimize its service offerings and strengthen partnerships with upstream suppliers to maintain service quality while achieving cost efficiency[49] - The group plans to enhance community-centered initiatives, including expanding oral health education programs and supporting vulnerable groups in collaboration with local governments[50] - The group is committed to reducing waste in clinical operations and promoting digital patient engagement tools[50] - The group is strategically investing in scalable technologies and standardized processes to ensure adaptability in a rapidly changing regulatory environment[49] - The group is focused on optimizing its cost structure to attract price-sensitive patients while ensuring service quality[41] - The group is establishing long-term partnerships with dental material suppliers to obtain better purchasing prices and improve internal management efficiency[41]
美皓集团(01947) - 2024 - 年度业绩